Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence.

about

Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence.

Item

http://www.wikidata.org/entity/Q52319542

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence.

@en

Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence.

@nl

type

Item

label

Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence.

@en

Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence.

@nl

prefLabel

Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence.

@en

Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence.

@nl

P1476

Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence.

@en

P2093

Camillo Porta

http://www.w3.org/2001/XMLSchema#string

Mimma Rizzo

http://www.w3.org/2001/XMLSchema#string

P2860

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma

Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases

Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature.

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.

Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.

P304

195-207

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1756287217713902

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29662544

http://www.w3.org/2001/XMLSchema#string

P932

5896861

http://www.w3.org/2001/XMLSchema#string